Cecilia Schwarzer

发表

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAFV600E colorectal tumors

R. Bernards, S. Vandenberg, K. Shokat, 2022, bioRxiv.

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

R. Bernards, S. Vandenberg, K. Shokat, 2023, Nature Cancer.